Dr. Steven Green -- Pharma Payment Report

Payment Summary

• Total Payments Received: $228.82
• Number of Transactions: 1
• Transparency Score: 50/100

Payment Breakdown

• speaking: $0.00
• travel: $0.00
• ownership: $0.00
• consulting: $0.00
• research: $0.00
• meals: $228.82

AI Analysis

Dr. Steven Green, a General Surgeon in City, MO, has a pharmaceutical payment profile that is notably minimal. With a total of $228.82 across a single payment, his financial interactions with the pharmaceutical industry are significantly lower than the average for his specialty. The sole recorded payment comes from Johnson & Johnson, amounting to $228.82, designated for meals. This singular transaction, dated June 1, 2025, suggests a very limited engagement, primarily involving modest hospitality rather than substantial financial ties like consulting, research, or speaking fees. Comparing Dr. Green's payment volume to his peers in General Surgery reveals a stark contrast. While many surgeons engage in various forms of collaboration with pharmaceutical companies, often involving significant sums for research, speaking engagements, or consulting, Dr. Green's profile indicates an almost complete absence of such relationships. The average general surgeon may receive thousands or even tens of thousands of dollars annually in various forms of compensation. His $228.82 total places him at the extreme low end of the spectrum, suggesting a deliberate choice to limit or avoid financial entanglements with drug manufacturers. This pattern of minimal engagement, specifically a single meal payment, does not suggest routine professional activity that would typically involve extensive collaboration. Instead, it points towards a professional practice that operates with a high degree of independence from pharmaceutical industry influence. For patients, this generally implies that treatment decisions are less likely to be influenced by financial incentives from drug companies. While any payment warrants transparency, the small amount and nature of this payment from Johnson & Johnson are unlikely to raise significant concerns about Dr. Green's clinical judgment. Patients should view this profile as indicative of a doctor who maintains a clear separation between pharmaceutical marketing and patient care, prioritizing objective medical decision-making. The transparency score reflects this minimal financial interaction.

Patient Guidance

When considering your doctor's relationship with pharmaceutical companies, it's important to remember that not all payments are inherently problematic. Many physicians engage in legitimate collaborations for research, education, or consulting that can benefit patient care. However, transparency is key. At your next appointment, you can ask your doctor about any financial relationships they have with drug or device manufacturers, especially if they are prescribing a new medication or recommending a specific treatment. Red flags to watch for include a doctor who consistently prescribes expensive brand-name drugs when cheaper, equally effective generics are available, or who seems overly enthusiastic about a particular drug or device without clear clinical justification. While a single meal payment like Dr. Green's is generally not a cause for concern, a pattern of frequent, high-value payments for meals, speaking, or consulting could warrant closer scrutiny. It's also helpful to look at the types of payments; research grants, for instance, can be legitimate avenues for advancing medical knowledge, whereas large sums for 'consulting' or 'speaker fees' without clear deliverables might be more indicative of marketing influence. Ultimately, evaluate your doctor's prescribing patterns and treatment recommendations based on evidence and your own understanding of your health needs. If you have persistent concerns, discussing them openly with your doctor or seeking a second opinion from a physician with a demonstrably independent practice can provide reassurance.

Peer Comparison

General surgeons typically engage with pharmaceutical companies in various capacities, leading to a wide range of payment volumes. While some surgeons receive no payments, many receive thousands of dollars annually for consulting, research, or speaking. The average payment for a general surgeon can range from a few hundred to several thousand dollars per year. Dr. Green's total of $228.82, attributed solely to meals, places him significantly below the average, indicating a minimal financial relationship with the pharmaceutical industry compared to his peers.

Recent Payments

Frequently Asked Questions

Is Dr. Steven Green taking too much pharma money?

Based on the available data, Dr. Steven Green has received a very minimal amount of pharmaceutical money, totaling $228.82 from a single meal payment. This is significantly lower than the average for General Surgery. While any payment warrants transparency, this amount and type of payment do not suggest an excessive financial relationship that would likely influence his medical judgment or patient care decisions. His profile indicates a strong separation from industry financial incentives.

What pharma companies pay Dr. Steven Green?

Dr. Steven Green has received payments from one pharmaceutical company: Johnson & Johnson. The total amount from this company is $228.82, which was for meals.

Should I switch doctors because of pharma payments?

Switching doctors solely based on minor pharmaceutical payments is generally not necessary. Dr. Green's payment profile is exceptionally low. Concerns might arise if a doctor has substantial financial ties and consistently prescribes expensive medications without clear justification, or if their recommendations seem heavily influenced by industry marketing. For Dr. Green, the minimal payment suggests a low risk of undue influence. Focus on your doctor's overall care, communication, and treatment outcomes.

What kinds of payments does this doctor receive?

Dr. Steven Green has received one type of payment: meals. The total amount for meals is $228.82 from Johnson & Johnson. He has not received payments for consulting, speaking, travel, research, or ownership.

How do these payments compare to other General Surgery?

Dr. Green's total payments of $228.82 are significantly lower than the average for General Surgery. While many surgeons receive thousands of dollars annually for various services, his profile indicates minimal financial interaction with pharmaceutical companies, primarily limited to a single meal payment.

Do pharma payments affect prescribing quality?

Research suggests that even small payments can subtly influence physician behavior, potentially leading to increased prescribing of the paying company's products. However, the impact varies greatly depending on the amount, type of payment, and individual physician. Dr. Green's minimal payment suggests a low likelihood of significant influence on his prescribing quality.

How can I verify this payment data?

You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. Visit the official CMS Open Payments website, search for Dr. Steven Green using his name and NPI (1975607885), and review the detailed records of payments reported by pharmaceutical companies and medical device manufacturers.